Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (Lausanne University Hospital)
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Universitaire Vaudois
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
An investigational fecal microbiota transplantation (FMT) therapy studied by Prof. Benoit Guery at the University Hospital of Lausanne, Switzerland, in a Phase III randomized controlled trial called FENDER. [4, 5, 6] The trial compares FMT administered as oral capsules following standard antibiotic treatment (vancomycin or fidaxomicin) against standard antibiotics alone for preventing recurrence in patients with a first episode or first recurrence of Clostridioides difficile infection (CDI). [2, 8] The therapy is a biologic treatment that involves administering fecal matter from healthy donors to restore gut microbiota balance. The active ingredient is the complete microbiota from donor stool. [3, 10] This study evaluates early intervention with FMT for CDI, in contrast to the established use of FMT for multiple recurrent CDI. [8]
- Other names
- FMTfecal microbiota transplant
Beyond the preview
Go deeper on fecal microbiota transplantation (Lausanne University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (Lausanne University Hospital).